5 comments

[ 2.8 ms ] story [ 15.1 ms ] thread
Link to the actual NEJM publication for those interested: https://www.nejm.org/doi/full/10.1056/NEJMoa2022483

Some interesting snippets:

“one participant in the 25-μg group was withdrawn because of an unsolicited adverse event, transient urticaria, judged to be related to the first vaccination.”

Also probably more important than antibodies: “The 25-μg and 100-μg doses elicited CD4 T-cell responses (Figs. S9 and S10) that on stimulation by S-specific peptide pools were strongly biased toward expression of Th1 cytokines (tumor necrosis factor α > interleukin 2 > interferon γ), with minimal type 2 helper T-cell (Th2) cytokine expression (interleukin 4 and interleukin 13). CD8 T-cell responses to S-2P were detected at low levels after the second vaccination in the 100-μg dose group (Fig. S11).”

Could you explain the snippet in plain English? Thanks!
They stopped the treatment for one person in the experiment group treated with 25 microgram dosage, because they showed a side-effect of itchy skin.

There is a bunch of white blood cells that produce things called cytokines which act as messengers on immune response. When you want to kill a pathogen you produce Th1. When you produce too much of it you risk killing your own tissue to cancel that you produce Th2. A balance between Th1 and Th2 is needed so that you don't kill yourself while trying to kill pathogens.

P.S.: not an immunologist.

> unsolicited adverse event ...

... as opposed to a solicited adversity? :)